

Supplementary Material to Koniecznyńska, Bryk, et al. “Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes” (<https://doi.org/10.1160/TH17-04-0259>)

Suppl. Table 1 Clot properties in patients with type 2 diabetes and cardiovascular disease (CVD)

Variables	Diabetic patients (n=200)	Control subjects (n=100)	p-value	Diabetic patients with CVD (n=127)	Diabetic patients without CVD (n=73)	p-value
$K_s, \times 10^{-9} \text{cm}^2$	7.0 (6.5-7.5)	6.9 (6.2-7.4)	0.005*	7.0 (6.2-7.5)	7.3 (6.9-7.5)	<0.001**
Lag _C , s	279 (223-352)	321 (315-327)	<0.001*	264 (218-341)	305 (234-374)	0.07**
Lag _L , s	277 (232-352)	328 (322-338)	<0.001*	262 (231-344)	306 (237-371)	0.05**
MaxAbs _C , au	0.34 (0.33-0.35)	0.33 (0.32-0.33)	<0.001*	0.34 (0.33-0.36)	0.33 (0.32-0.34)	<0.001**
MaxAbs _L , au	0.31 (0.29-0.33)	0.31 (0.29-0.31)	0.044*	0.31 (0.30-0.33)	0.30 (0.29-0.32)	0.005**
CR _C , $\times 10^{-4}$ au/s	2.76 (2.39-2.98)	2.38 (2.17-2.49)	<0.001*	2.75 (2.43-2.97)	2.78 (2.21-3.01)	0.6**
CR _L , $\times 10^{-4}$ au/s	2.81 (2.39-3.49)	2.73 (2.42-2.88)	0.002*	2.82 (2.43-3.55)	2.77 (2.27-3.40)	0.9**
Lys50 _{t0} , s	3030 (2245-3800)	2600 (2445-2660)	<0.001*	3260 (2410-3870)	2780 (2070-3430)	0.06**
Lys50 _{MA} , s	1400 (1180-1640)	1200 (1100-1265)	<0.001*	1470 (1170-1670)	1330 (1190-1530)	0.8**
Lys _T , s	6505 (5330-7860)	5525 (5330-5725)	0.005*	6470 (5200-8130)	6520 (5420-7330)	0.1**
LR	0.43 (0.38-0.49)	0.46 (0.45-0.47)	<0.001*	0.45 (0.39-0.49)	0.39 (0.38-0.47)	0.3**
AUC	844 (734-969)	600 (503-700)	<.001*	890 (773-983)	770 (697-914)	0.008**

* p-value adjusted for age, obesity, smoking, high sensitivity-CRP, fibrinogen, glucose;

** p-value adjusted for age, creatinine, fibrinogen and glucose.

Supplementary Material to Koniecznyńska, Bryk, et al. “Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes” (<https://doi.org/10.1160/TH17-04-0259>)

Data presented as the median and interquartile range and the p-value calculated in the Mann-Whitney’s test. K_s denotes permeation coefficient; Lag_C , clotting lag time; Lag_L , lysis lag time; $MaxAbs_C$, clotting maximum absorbance; $MaxAbs_L$, lysis maximum absorbance; CR_C , clotting clot rate; CR_L , lysis clot rate; $Lys50_{t0}$, $Lys50_{MA}$, Lys_T , lysis times; LR, lysis rate; AUC, area under curve.

Suppl. Table 2 Contribution of cellular fibronectin (cFn) to the variance of the turbidimetric parameters in diabetic patients.

Variables	R ²	p-value	R ² *	p-value *
$K_s, \times 10^{-9} \text{cm}^2$	3.73%	0.006	10.19%	0.047
Lag_C, s	1.99%	0.046	4.98%	0.07
Lag_L, s	1.93%	0.049	4.09%	0.1
$MaxAbs_C, \text{au}$	14.16%	<0.001	18.16%	<0.001
$MaxAbs_L, \text{au}$	3.29%	0.010	6.56%	0.022
$CR_C, \times 10^{-4} \text{au/s}$	0.04%	0.8	2.02%	0.6
$CR_L, \times 10^{-4} \text{au/s}$	0.17%	0.6	3.82%	0.5
$Lys50_{t0}, \text{s}$	0.56%	0.3	1.66%	0.7
$Lys50_{MA}, \text{s}$	0.04%	0.8	1.64%	0.6
Lys_T, s	0.09%	0.7	2.15%	0.6
LR	0.37%	0.4	2.91%	0.3
AUC	5.64%	<0.001	8.64%	0.002

* adjusted for age, fibrinogen, creatinine and glucose.

Data demonstrated as the pseudo-R² and p-value calculated in the linear regression. For abbreviations

Supplementary Material to Koniecznyńska, Bryk, et al. "Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes" (<https://doi.org/10.1160/TH17-04-0259>)

see Suppl. Table 1.

Suppl. Table 3 Univariate and multivariate model predictors of the lowest quartile of clot permeability (K_s) and top quartile of clot density (MaxAbs_C), lysis time (LysT) and area under the curve (AUC) in control subjects.

Variables	Univariate OR (95% CI)	p-value	Multivariate OR (95% CI)	p-value
K_s				
BMI, kg/m ²	0.89 (0.77-1.02)	0.1	-	-
Cardiovascular disease	2.96 (0.91-10.49)	0.1	-	-
Angiotensin receptor blocker	0.19 (0.01-1.42)	0.1	-	-
Hemoglobin, g/dl	1.34 (0.87-2.12)	0.2	-	-
INR	0.002 (0.00-4.70)	0.1	-	-
Fibrinogen, g/l	4.27 (1.83-13.08)	<0.001	12.79 (1.15-141.94)	0.005
Creatinine, μmol/l	0.93 (0.88-0.98)	0.008	0.85 (0.76-0.96)	<0.001
hs-CRP, mg/l	0.72 (0.49-1.01)	0.060	-	-
cFn, ug/ml	65.36 (9.67-815.77)	<0.001	168.40 (7.27-3900.10)	<0.001
MaxAbs_C				
Age, years	1.12 (1.06-1.20)	<0.001	-	-

Supplementary Material to Koniecznyńska, Bryk, et al. “Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes” (<https://doi.org/10.1160/TH17-04-0259>)

Suppl. Table 3 Univariate and multivariate model predictors of the lowest quartile of clot permeability (K_s) and top quartile of clot density (MaxAbsC), lysis time (LysT) and area under the curve (AUC) in control subjects.

Variables	Univariate OR (95% CI)	p-value	Multivariate OR (95% CI)	p-value
K_s				
Obesity	0.43 (0.12-1.40)	0.2	-	-
Smoking	8.00 (1.80-56.91)	0.005	-	-
Beta-blocker	3.61 (1.12-12.75)	0.031	-	-
Statin	0.41 (0.13-1.25)	0.1	-	-
Fibrinogen, g/l	4.64 (1.87-15.82)	<0.001	27.57 (0.78-980.78)	0.007
APTT	1.21 (1.03-1.46)	0.016	-	-
Alanine aminotransferase	0.93 (0.85-1.01)	0.10	-	-
Total cholesterol, mmol/l	1.02 (1.01-1.04)	<0.001	1.08 (1.02-1.14)	<0.001
Low-density lipoprotein, mmol/l	1.04 (1.02-1.06)	<0.001	-	-
High-density lipoprotein, mmol/l	1.09 (1.05-1.14)	<0.001	-	-
Triglycerides, mmol/l	1.03 (1.015-1.05)	<0.001	0.95 (0.90-1.00)	0.018
Glucose, mmol/l	0.29 (0.084-0.80)	0.016	-	-
cFn ug/ml	28.49 (5.72-232.74)	<0.001	1679.64 (4.61-611836.5)	<0.001
Lys_T				
Female gender	0.35 (0.11-1.06)	0.064	2.90 (0.92-9.11)	0.064
Angiotensin converting enzyme inhibitor	0.48 (0.15-1.46)	0.2	-	-

Supplementary Material to Koniecznyńska, Bryk, et al. “Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes” (<https://doi.org/10.1160/TH17-04-0259>)

Suppl. Table 3 Univariate and multivariate model predictors of the lowest quartile of clot permeability (K_s) and top quartile of clot density (MaxAbsC), lysis time (LysT) and area under the curve (AUC) in control subjects.

Variables	Univariate OR (95% CI)	p-value	Multivariate OR (95% CI)	p-value
K_s				
Fibrinogen, g/l	1.75 (0.88-3.74)	0.1	-	-
AUC				
Age, years	1.11 (1.05-1.12)	<0.001	-	-
Obesity	0.32 (0.07-1.15)	0.08	-	-
Aspirin	0.43 (0.13-1.34)	0.2	-	-
Statin	0.34 (0.10-1.10)	0.07	-	-
Fibrinogen, g/l	4.29 (1.89-12.45)	<0.001	-	-
APTT	1.53 (1.21-2.10)	<0.001	-	-
Total cholesterol, mmol/l	1.02 (1.01-1.04)	<0.001	3.19 (0.47-21.63)	0.035
Low-density lipoprotein, mmol/l	1.04 (1.03-1.06)	<0.001	0.31 (0.05-2.15)	0.039
High-density lipoprotein, mmol/l	1.07 (1.04-1.12)	<0.001	0.32 (0.05-2.16)	0.041
Triglycerides, mmol/l	1.03 (1.02-1.06)	<0.001	0.82 (0.56-1.19)	0.055
Glucose, mmol/l	0.35 (0.10-0.99)	0.048	-	-
cFn ug/ml	33.72 (5.54-351.13)	<0.001	81.58 (2.27-2935.18)	<0.001

Results were presented as the odds ratio (OR) and 95% confidence interval (95% CI) and p-value calculated in the logistic regression. The variables with p-value less than 0.2 in the univariate regression were included in the stepwise backwards regression minimalizing Akaike Information Criterion to establish the multivariate

Supplementary Material to Koniecznyńska, Bryk, et al. “Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes” (<https://doi.org/10.1160/TH17-04-0259>)

Suppl. Table 3 Univariate and multivariate model predictors of the lowest quartile of clot permeability (Ks) and top quartile of clot density (MaxAbsC), lysis time (LysT) and area under the curve (AUC) in control subjects.

Variables	Univariate OR (95% CI)	p-value	Multivariate OR (95% CI)	p-value
-----------	------------------------	---------	--------------------------	---------

K_s

model. cFn denotes cellular fibronectin; aPTT, activated partial thromboplastin time. For other abbreviations see Suppl. Table 1.